Lowest-Rated StocksLowest-RatedNYSE:NVRO Nevro (NVRO) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free NVRO Stock Alerts $14.44 +0.02 (+0.14%) (As of 04:38 PM ET) Add Compare Share Share Today's Range$14.28▼$14.7050-Day Range$13.56▼$19.0152-Week Range$13.36▼$39.67Volume332,027 shsAverage Volume488,835 shsMarket Capitalization$525.62 millionP/E RatioN/ADividend YieldN/APrice Target$23.23 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nevro alerts: Email Address Nevro MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside60.9% Upside$23.23 Price TargetShort InterestBearish12.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.53) to ($2.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.25 out of 5 starsMedical Sector771st out of 938 stocksSurgical & Medical Instruments Industry80th out of 97 stocks 3.0 Analyst's Opinion Consensus RatingNevro has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 11 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.23, Nevro has a forecasted upside of 60.9% from its current price of $14.44.Amount of Analyst CoverageNevro has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.11% of the float of Nevro has been sold short.Short Interest Ratio / Days to CoverNevro has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Nevro has recently decreased by 3.90%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNevro does not currently pay a dividend.Dividend GrowthNevro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVRO. Previous Next 1.8 News and Social Media Coverage News SentimentNevro has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nevro this week, compared to 3 articles on an average week.Search Interest1 people have searched for NVRO on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Nevro to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nevro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Nevro is held by insiders.Percentage Held by Institutions95.52% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nevro are expected to grow in the coming year, from ($2.53) to ($2.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nevro is -5.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nevro is -5.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNevro has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow you can target big results without spending big money!While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades! Click here so I can share the details of my $0.25 Cent Trades About Nevro Stock (NYSE:NVRO)Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation system for the treatment of chronic pain, as well as Senza II and Senza Omnia SCS systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company's Senza HFX iQ IPG system includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.Read More NVRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVRO Stock News HeadlinesMarch 25, 2024 | finanznachrichten.deEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationMarch 18, 2024 | americanbankingnews.comNevro Corp. (NYSE:NVRO) Receives Average Rating of "Hold" from AnalystsMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 11, 2024 | finance.yahoo.comNVRO Mar 2024 20.000 putFebruary 28, 2024 | prnewswire.comNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)February 26, 2024 | markets.businessinsider.comNevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market UncertaintyFebruary 23, 2024 | realmoney.thestreet.comNevro just downgraded at Oppenheimer, here's whyMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionFebruary 22, 2024 | finanznachrichten.deNevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsFebruary 22, 2024 | fool.comWhy Nevro Stock Lagged the Market on ThursdayFebruary 22, 2024 | markets.businessinsider.comHold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 OutlookFebruary 22, 2024 | markets.businessinsider.comAnalyst Scoreboard: 4 Ratings For NevroFebruary 22, 2024 | finance.yahoo.comNevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | washingtonpost.comNevro: Q4 Earnings SnapshotFebruary 21, 2024 | msn.comNevro GAAP EPS of -$0.25 beats by $0.24, revenue of $116.17M beats by $0.17MFebruary 21, 2024 | finance.yahoo.comNevro Corp (NVRO) Reports Modest Revenue Growth Amidst Strategic ShiftsFebruary 21, 2024 | finance.yahoo.comNevro (NVRO) Reports Q4 Loss, Tops Revenue EstimatesFebruary 21, 2024 | prnewswire.comNevro Enters Into Cooperation Agreement With Engaged CapitalFebruary 21, 2024 | prnewswire.comNevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsFebruary 20, 2024 | markets.businessinsider.comNevro is about to announce its earnings — here's what Wall Street expectsFebruary 17, 2024 | finance.yahoo.comNVRO Mar 2024 22.500 callFebruary 3, 2024 | money.usnews.comNevro CorpJanuary 29, 2024 | finance.yahoo.comNevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024January 19, 2024 | finance.yahoo.comNevro's (NVRO) SCS Therapy Gets Positive Coverage UpdateJanuary 18, 2024 | finance.yahoo.comNevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic NeuropathyJanuary 17, 2024 | finance.yahoo.comNevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual MeetingSee More Headlines Receive NVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today3/28/2024Next Earnings (Estimated)4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:NVRO CUSIPN/A CIK1444380 Webwww.nevro.com Phone(650) 251-0005FaxN/AEmployees1,215Year FoundedN/APrice Target and Rating Average Stock Price Target$23.23 High Stock Price Target$40.00 Low Stock Price Target$15.00 Potential Upside/Downside+60.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,210,000.00 Net Margins-21.69% Pretax Margin-23.02% Return on Equity-30.22% Return on Assets-15.17% Debt Debt-to-Equity Ratio0.72 Current Ratio6.37 Quick Ratio4.94 Sales & Book Value Annual Sales$425.17 million Price / Sales1.24 Cash FlowN/A Price / Cash FlowN/A Book Value$8.10 per share Price / Book1.79Miscellaneous Outstanding Shares36,400,000Free Float35,306,000Market Cap$526.34 million OptionableOptionable Beta0.91 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Roderick H. MacLeod (Age 57)Senior VP & CFO Comp: $729.61kMr. Kashif Rashid (Age 50)Senior VP, General Counsel & Corporate Secretary Comp: $703.35kMr. Kevin R. Thornal (Age 50)President, CEO & Director Mr. Richard B. Carter (Age 53)Chief Accounting Officer Mr. Christofer Christoforou (Age 54)Senior Vice President of Technical Operations Comp: $367.4kGeeta KavetiVP and Chief Compliance & Privacy OfficerMr. Jon R. ShearSenior Vice President of Corporate DevelopmentMeredith VornholtVice President of Global MarketingMs. Shana D. Ross M.B.A.Senior VP & Chief of Human Resources OfficerDr. David Caraway M.D. (Age 67)Ph.D., Senior VP & Chief Medical Officer More ExecutivesKey CompetitorsOrthofix MedicalNASDAQ:OFIXOraSure TechnologiesNASDAQ:OSURPulse BiosciencesNASDAQ:PLSEBeauty HealthNASDAQ:SKINIradimedNASDAQ:IRMDView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Bought 13,000 shares on 3/27/2024Ownership: 0.163%Vanguard Group Inc.Sold 164,634 shares on 3/11/2024Ownership: 11.174%Goldman Sachs Group Inc.Bought 431,136 shares on 3/1/2024Ownership: 2.879%Price T Rowe Associates Inc. MDBought 1,583 shares on 2/16/2024Ownership: 0.105%Nuveen Asset Management LLCBought 866 shares on 2/15/2024Ownership: 0.624%View All Insider TransactionsView All Institutional Transactions NVRO Stock Analysis - Frequently Asked Questions Should I buy or sell Nevro stock right now? 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 1 sell rating, 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares. View NVRO analyst ratings or view top-rated stocks. What is Nevro's stock price target for 2024? 13 equities research analysts have issued 12 month price targets for Nevro's stock. Their NVRO share price targets range from $15.00 to $40.00. On average, they expect the company's stock price to reach $23.23 in the next year. This suggests a possible upside of 60.9% from the stock's current price. View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts. How have NVRO shares performed in 2024? Nevro's stock was trading at $21.52 at the start of the year. Since then, NVRO stock has decreased by 32.9% and is now trading at $14.44. View the best growth stocks for 2024 here. When is Nevro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our NVRO earnings forecast. How were Nevro's earnings last quarter? Nevro Corp. (NYSE:NVRO) posted its earnings results on Wednesday, February, 21st. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.35. The medical equipment provider had revenue of $116.18 million for the quarter, compared to analysts' expectations of $115.93 million. Nevro had a negative trailing twelve-month return on equity of 30.22% and a negative net margin of 21.69%. What ETFs hold Nevro's stock? ETFs with the largest weight of Nevro (NYSE:NVRO) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), iShares Neuroscience and Healthcare ETF (IBRN) and SPDR S&P Health Care Equipment ETF (XHE).Fidelity Digital Health ETF (FDHT). What guidance has Nevro issued on next quarter's earnings? Nevro updated its first quarter 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $97.0 million-$99.0 million, compared to the consensus revenue estimate of $98.7 million. What is D. Keith Grossman's approval rating as Nevro's CEO? 9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees. What other stocks do shareholders of Nevro own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG). Who are Nevro's major shareholders? Nevro's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.23%), Vanguard Group Inc. (11.17%), Armistice Capital LLC (8.77%), Braidwell LP (4.91%), Goldman Sachs Group Inc. (2.89%) and Goldman Sachs Group Inc. (2.88%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane and Shawn Mccormick. View institutional ownership trends. How do I buy shares of Nevro? Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NVRO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill PublishingAI to Meet the Same Fate as EVs? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.